Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement inhibitory therapeutics and xenotransplantation

U S Ryan1

  • 1T Cell Sciences, Inc., Needham, Massachusetts 02194, USA.

Nature Medicine
|September 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Receptor-dependent regulation of [Ca2+]i and phospholipase C in vascular endothelial cells.

Journal of receptor and signal transduction research·2001
Same author

Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis.

Arteriosclerosis, thrombosis, and vascular biology·2000
Same author

Blockade of complement inhibits obliterative bronchiolitis in rat tracheal allografts.

American journal of respiratory and critical care medicine·2000
Same author

Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein.

Nature medicine·1999
Same author

Endothelial targeting and enhanced antiinflammatory effects of complement inhibitors possessing sialyl Lewisx moieties.

Journal of immunology (Baltimore, Md. : 1950)·1999
Same author

Studies on the mechanisms involved in antigen-evoked pleural inflammation in rats: contribution of IgE and complement.

Journal of leukocyte biology·1997

Inhibiting complement activation is crucial for xenotransplantation success. Soluble complement receptor type 1 offers a controllable therapeutic option to manage immune responses and rejection in organ transplantation.

Area of Science:

  • Immunology
  • Transplantation Biology
  • Biochemistry

Background:

  • Xenotransplantation faces significant hurdles, including hyperacute rejection (HAR) mediated by the complement system.
  • Effective inhibition of complement activation is a prerequisite for clinical xenotransplantation viability.

Purpose of the Study:

  • To highlight the necessity of controlling complement-mediated immune responses in xenotransplantation.
  • To present soluble complement receptor type 1 (sCR1) as a potential therapeutic agent.

Main Methods:

  • Discussion of complement inhibition strategies in the context of xenotransplantation.
  • Focus on the therapeutic potential of soluble complement receptor type 1 (sCR1).

Main Results:

Related Experiment Videos

  • Complement-mediated HAR must be addressed for xenotransplantation.
  • sCR1 offers a clinically relevant method for inhibiting complement activation.
  • sCR1 allows for physician-controlled, adaptable dosing regimens.

Conclusions:

  • Effective complement inhibition is essential for overcoming xenotransplantation barriers.
  • Soluble complement receptor type 1 presents a viable therapeutic strategy for managing xenograft rejection.
  • The adjustable dosing of sCR1 enhances its clinical applicability in transplantation.